Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Psychiatric disorders – page 7

  • 548 clinical trials
  • 257 recruiting
  • 147 conditions
  • 26 countries

Conditions in this area

147 conditions with trials, the busiest first

Dementia Alzheimer's type87Major depression57Schizophrenia40Depression35Narcolepsy19Cognitive disorder18Bipolar disorder16Autism spectrum disorder15Insomnia15Post-traumatic stress disorder14Psychotic disorder14Drug use disorder13Alcohol use disorder12Attention deficit hyperactivity disorder9Dementia9Obstructive sleep apnoea syndrome9Brain injury8Irritable bowel syndrome8Phenylketonuria8Bipolar I disorder7Drug dependence7Hypersomnia7Lennox-Gastaut syndrome7Anorexia nervosa6+123

Clinical trials in Psychiatric disorders

548 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

548 clinical trials

Major depression

Recruiting

Study of D-cycloserine with theta-burst brain stimulation for adults with major depressive disorder

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cycloserine
  • Sponsor:Region Uppsala

Epileptic encephalopathy

Recruiting

Study of Elsunersen in Children with SCN2A Developmental and Epileptic Encephalopathy to Reduce Seizures

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:5'-MOEMC-(SP)-MOEMC-(P)-MOEA-(P)-MOEMC-(P)-MOEG-(P)-MOEA-(P)-DMC-(SP)-DA-(SP)-DT-(SP)-DA-(SP)-DT-(SP)-DT-(SP)-DT-(SP)-DT-(SP)-DT-(SP)-DMC-(SP)-MOET-(P)-MOEA-(SP)-MOEMC-(SP)-MOEA 3'
  • Sponsor:Praxis Precision Medicines Inc.

Neurodevelopmental disorder

Recruiting

Study of levodopa and carbidopa treatment for patients with neurodevelopmental disorder caused by CTNNB1 gene mutation

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Carbidopa
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Epileptic encephalopathy

Recruiting

Study of intrathecal S230815 to evaluate safety and effectiveness in children with KCNT1-related Developmental and Epileptic Encephalopathy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:S230815-2
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Irritable bowel syndrome

Recruiting

Study of Saccharomyces boulardii CNCM I-745 to treat symptoms in adults with non-constipated Irritable Bowel Syndrome

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Loperamide Hydrochloride
  • Sponsor:Biocodex

Bipolar I disorder+1

Recruiting

Long-term safety study of trospium chloride and xanomeline tartrate combination (KarXT) for treatment of manic episodes in adults with Bipolar I Disorder

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Bipolar I disorder+1

Recruiting

Study of trospium chloride and xanomeline tartrate (KarXT) for treating manic episodes in adults with bipolar I disorder

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Bipolar I disorder+1

Recruiting

Study of trospium chloride and xanomeline tartrate (KarXT) for treatment of manic episodes in adults with bipolar I disorder

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Depression

Recruiting

Study of psilocybin compared to personalized rTMS treatment in adults with treatment-resistant depression

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Dry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol
  • Sponsor:Universita' Degli Studi G. D'Annunzio Di Chieti

Major depression

Recruiting

Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Breast cancer female+2

Recruiting

A Study of Oxytocin Nasal Spray to Reduce Psychological Stress in Women Who Have Recovered from Breast Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Oxytocin
  • Sponsor:UZ Leuven

Major depression

Recruiting

Study of deupsilocin besilate (CYB003) in adults with major depressive disorder comparing two doses against placebo

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Deupsilocin besilate
  • Sponsor:Cybin IRL Limited

Substances studied in this area

The therapies tested most often in Psychiatric disorders trials.

Sodium Chloride25 clinical trialsTrospium Chloride18 clinical trialsXanomeline Tartrate17 clinical trialsCannabidiol15 clinical trialsDry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol14 clinical trialsFlorquinitau (18F)14 clinical trialsOxytocin13 clinical trialsAripiprazole12 clinical trialsFlorbetaben (18F)12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.